Coeptis Therapeutics (NASDAQ:ZSQR – Get Free Report) and Nvni Group (NASDAQ:NVNI – Get Free Report) are both small-cap technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.
Analyst Recommendations
This is a summary of current recommendations and price targets for Coeptis Therapeutics and Nvni Group, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Coeptis Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Nvni Group | 1 | 1 | 0 | 0 | 1.50 |
Valuation & Earnings
This table compares Coeptis Therapeutics and Nvni Group”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Coeptis Therapeutics | $1.36 million | 142.24 | -$11.92 million | ($1.63) | -2.24 |
| Nvni Group | $196.74 million | 0.05 | -$20.22 million | $0.40 | 2.60 |
Coeptis Therapeutics has higher earnings, but lower revenue than Nvni Group. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Nvni Group, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 0.5% of Nvni Group shares are owned by institutional investors. 24.2% of Coeptis Therapeutics shares are owned by company insiders. Comparatively, 20.0% of Nvni Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Coeptis Therapeutics and Nvni Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Coeptis Therapeutics | -773.72% | -49.45% | -46.88% |
| Nvni Group | N/A | N/A | N/A |
Risk and Volatility
Coeptis Therapeutics has a beta of -0.19, meaning that its stock price is 119% less volatile than the S&P 500. Comparatively, Nvni Group has a beta of -0.07, meaning that its stock price is 107% less volatile than the S&P 500.
Summary
Nvni Group beats Coeptis Therapeutics on 8 of the 12 factors compared between the two stocks.
About Coeptis Therapeutics
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
About Nvni Group
Nvni Group Limited provides a business to business SaaS platform that offers cloud solutions. The company was incorporated in 2019 and is based in São Paulo, Brazil.
Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
